Research programme: immuno-oncology therapeutics - e-Therapeutics
Latest Information Update: 28 Apr 2022
Price :
$50 *
At a glance
- Originator e-Therapeutics
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for research development in Cancer in United Kingdom
- 27 Mar 2018 Early research in Cancer in United Kingdom (unspecified route)